Indications |
Oral Depression Adult: Initially, 50 mg once daily, may increase in steps of 50 mg at wkly intervals. Max: 200 mg daily. Child: For obsessive-compulsive disorder: 6-12 yr: Initially, 25 mg once daily; 13-17 yr: Initially, 50 mg once daily. May increase dose at intervals of at least 1 wk, to a max of 200 mg/day. If somnolence is noted, give at bedtime. Hepatic impairment: Dosage reduction may be required. Oral Obsessive compulsive disorder Adult: Initially, 50 mg once daily, may increase in steps of 50 mg at wkly intervals. Max: 200 mg daily. Child: For obsessive-compulsive disorder: 6-12 yr: Initially, 25 mg once daily; 13-17 yr: Initially, 50 mg once daily. May increase dose at intervals of at least 1 wk, to a max of 200 mg/day. If somnolence is noted, give at bedtime. Hepatic impairment: Dosage reduction may be required. Oral Panic disorder with or without agoraphobia Adult: Initially, 25 mg daily, increased after 1 wk to 50 mg daily. May increase in steps of 50 mg at wkly intervals. Max: 200 mg daily. Hepatic impairment: Dosage reduction may be required. Oral Posttraumatic stress disorder Adult: Initially, 25 mg daily, increased after 1 wk to 50 mg daily. May increase in steps of 50 mg at wkly intervals. Max: 200 mg daily. Hepatic impairment: Dosage reduction may be required. Oral Social anxiety disorder Adult: Initially, 25 mg daily, increased after 1 wk to 50 mg daily. May increase in steps of 50 mg at wkly intervals. Max: 200 mg daily. Hepatic impairment: Dosage reduction may be required. Oral Premenstrual dysphoric disorder Adult: Initially, 50 mg daily. May be given throughout the menstrual cycle or only during the luteal phase. May increase by 50 mg each cycle if needed. Max: 150 mg daily for continuous dosing or 100 mg daily for luteal phase-only dosing. Patients who require 100 mg daily for luteal phase-only dosing should always start with 50 mg daily for the 1st 3 days of each luteal phase dosing period. Hepatic impairment: Dosage reduction may be required. Special Populations: Hepatic/Renal impairment: Either lower dose or less frequent dosage is preferred. |
Contraindications |
Children <18 yr. Poorly controlled epilepsy. |
Warnings / Precautions |
History of hypomania and seizure disorders, hepatic and renal impairment, cardiac disease, recent MI, history of bleeding disorders, DM and angle-closure glaucoma. Discontinue treatment if seizures develop or if there is an increase in seizure frequency. Withdrawal should be gradual. Monitor for signs of clinical worsening, suicidality and unusual changes in behaviour especially during the initial treatment period or when there are dosage adjustments. Pregnancy and lactation. |
Adverse Reactions |
Nausea, anorexia, dyspepsia, constipation, diarrhoea, dry mouth, flatulence, vomiting, ejaculation failure, increased sweating, somnolence, agitation, insomnia, headache, dizziness, fatigue, anxiety, nervousness, tremor, paraesthesia, decreased libido, rash, hot flushes, blurred vision. |
Overdose Reactions |
Symptoms include nausea, vomiting and CNS excitation. May lead to death. |
Drug Interactions |
May increase risk of delirium when used with antimuscarinics. Increased risk of extrapyramidal symptoms and neuroleptic malignant syndrome when used with aripiprazole. Serum levels may be reduced by carbamazepine. Concurrent use with dihydroergotamine or linezolid may lead to serotonin syndrome. May increase serum levels of lamotrigine and risk of toxicity. May increase serum levels of olanzapine, pimozide, risperidone, methadone, clozapine and amiodarone. Plasma levels may be increased by cimetidine and ritonavir. May increase the anticoagulant activity of warfarin and acenocoumarol. Potentially Fatal: Concomitant admin with MAOIs can result in serious serotonin syndrome. See Below for More sertraline Drug Interactions |
Food Interactions |
Co-admin with food increases peak plasma concentration of sertraline. Plasma levels are increased by grapefruit juice. |
Mechanism of Actions |
Sertraline has a potent and selective inhibitory action on CNS neuronal reuptake of 5-HT resulting in increased 5-HT concentrations at the synaptic clefts, leading to sustained activity at the postsynaptic receptor sites and improvement of depression. Reduction of serotonin turnover (in brain) also contributes to its action. Its long half-life allows once daily admin. Absorption: Absorbed slowly from the GI tract (oral); plasma concentrations peak 4.5-8.5 hr after oral admin. Distribution: Body tissues (wide), enters breast milk. Protein-binding: 98%. Metabolism: Extensive hepatic first-pass metabolism; demethylation to N-desmethylsertraline (inactive) then to glucuronide conjugates. Excretion: Via urine and faeces (as metabolites); elimination half-life: about 26 hr. |
Administration |
May be taken with or without food. |
Storage Conditions |
Oral: Store at 15-30°C. |
ATC Classification |
N06AB06 - sertraline ; Belongs to the class of selective serotonin reuptake inhibitors. Used in the management of depression. |
Storage |
Oral: Store at 15-30°C. |
Available As |
|
Sertraline
One Response to Sertraline
Post Review about Sertraline Click here to cancel reply.
Sertraline Containing Brands
Sertraline is used in following diseases
Drug - Drug Interactions of Sertraline
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
Am currently taking zoloft(generic)100mg just increased it to 150mg what effects should i excpect? When or what is the right dose for me? How can i determine that? Please respond this message. Thank you.